keyword
MENU ▼
Read by QxMD icon Read
search

melanoma Stage 3

keyword
https://www.readbyqxmd.com/read/29049612/long-term-change-in-the-risk-of-skin-cancer-after-organ-transplantation-a-population-based-nationwide-cohort-study
#1
Syed Mohammad Husain Rizvi, Bjarte Aagnes, Hallvard Holdaas, Einar Gude, Kristin Muri Boberg, Øystein Bjørtuft, Per Helsing, Torbjørn Leivestad, Bjørn Møller, Petter Gjersvik
Importance: The high risk of skin cancer after organ transplantation is a major clinical challenge and well documented, but reports on temporal trends in the risk of posttransplant cutaneous squamous cell carcinoma (SCC) are few and appear contradictory. Objective: To study temporal trends for the risk of skin cancer, particularly SCC, after organ transplantation. Design, Setting, and Participants: Population-based, nationwide, prospective cohort study of 8026 patients receiving a kidney, heart, lung, or liver transplant in Norway from 1968 through 2012 using patient data linked to a national cancer registry...
October 18, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/29049462/association-of-surgical-approach-and-margin-status-with-oncologic-outcomes-following-gross-total-resection-for-sinonasal-melanoma
#2
Zafar Sayed, Jocelyn C Migliacci, Jennifer R Cracchiolo, Christopher A Barker, Nancy Y Lee, Sean M McBride, Viviane S Tabar, Ian Ganly, Snehal G Patel, Luc T Morris, Benjamin R Roman, Alexander N Shoushtari, Marc A Cohen
Importance: Sinonasal mucosal melanoma (SMM) is a rare malignant neoplasm characterized by a poor prognosis despite aggressive intervention including wide surgical resection. Margin status has previously been cited as an important prognostic factor for local control and overall survival (OS) in patients who undergo either an open or endoscopic surgical approach. No comparisons have been made, however, in patients who have undergone gross total resection with or without positive margins...
October 19, 2017: JAMA Otolaryngology—Head & Neck Surgery
https://www.readbyqxmd.com/read/29044496/ncctg-n0879-alliance-a-randomized-phase-2-cooperative-group-trial-of-carboplatin-paclitaxel-and-bevacizumab%C3%A2-%C3%A2-%C3%A2-everolimus-for-metastatic-melanoma
#3
Robert R McWilliams, Jacob B Allred, Jessica A Slostad, Rajini Katipamula, Roxana S Dronca, Kandelaria M Rumilla, Lori A Erickson, Alan H Bryce, Richard W Joseph, Lisa A Kottschade, David M King, John M Leitch, Svetomir N Markovic
BACKGROUND: Despite the success of immune checkpoint and targeted therapy, many patients with melanoma ultimately require further treatment. The combination of carboplatin, paclitaxel, and bevacizumab (CPB) has demonstrated promising activity in a single-arm study. In the current study, the authors performed a randomized phase 2 study to confirm efficacy and to determine whether adding everolimus would increase the activity of the combination. METHODS: Through the North Central Cancer Treatment Group, a total of 149 patients with unresectable AJCC 6th edition stage IV melanoma were randomized from May 2010 to May 2014 to either CPB or CPB with everolimus (CPBE)...
October 17, 2017: Cancer
https://www.readbyqxmd.com/read/29028788/efficacy-and-safety-of-pembrolizumab-in-patients-enrolled-in-keynote-030-in-the-united-states-an-expanded-access-program
#4
Tara C Gangadhar, Wen-Jen Hwu, Michael A Postow, Omid Hamid, Adil Daud, Roxana Dronca, Richard Joseph, Steven J O'Day, F S Hodi, Anna C Pavlick, Harriet Kluger, Romina P Oxborough, Aiming Yang, Mihaela Gazdoiu, Debra A Kush, Scot Ebbinghaus, April K S Salama
KEYNOTE-030 (ClinicalTrials.gov ID, NCT02083484) was a global expanded access program that allowed access to pembrolizumab, an antiprogrammed death 1 antibody, for patients with advanced melanoma before its regulatory approval. Patients with unresectable stage III/IV melanoma that progressed after standard-of-care therapy, including ipilimumab and, if BRAF mutant, a BRAF inhibitor, were eligible to receive pembrolizumab 2 mg/kg every 3 weeks. Response was assessed by immune-related response criteria by investigator review...
November 2017: Journal of Immunotherapy
https://www.readbyqxmd.com/read/29028110/melanoma-staging-evidence-based-changes-in-the-american-joint-committee-on-cancer-eighth-edition-cancer-staging-manual
#5
Jeffrey E Gershenwald, Richard A Scolyer, Kenneth R Hess, Vernon K Sondak, Georgina V Long, Merrick I Ross, Alexander J Lazar, Mark B Faries, John M Kirkwood, Grant A McArthur, Lauren E Haydu, Alexander M M Eggermont, Keith T Flaherty, Charles M Balch, John F Thompson
Answer questions and earn CME/CNE To update the melanoma staging system of the American Joint Committee on Cancer (AJCC) a large database was assembled comprising >46,000 patients from 10 centers worldwide with stages I, II, and III melanoma diagnosed since 1998. Based on analyses of this new database, the existing seventh edition AJCC stage IV database, and contemporary clinical trial data, the AJCC Melanoma Expert Panel introduced several important changes to the Tumor, Nodes, Metastasis (TNM) classification and stage grouping criteria...
October 13, 2017: CA: a Cancer Journal for Clinicians
https://www.readbyqxmd.com/read/29019177/long-term-survival-after-complete-surgical-resection-and-adjuvant-immunotherapy-for-distant-melanoma-metastases
#6
Mark B Faries, Nicola Mozzillo, Mohammed Kashani-Sabet, John F Thompson, Mark C Kelley, Ronald C DeConti, Jeffrey E Lee, James F Huth, Jeffrey Wagner, Angus Dalgleish, Daniel Pertschuk, Christopher Nardo, Stacey Stern, Robert Elashoff, Guy Gammon, Donald L Morton
BACKGROUND: This phase III study was undertaken to evaluate the efficacy of an allogeneic whole-cell vaccine (Canvaxin™) plus bacillus Calmette-Guerin (BCG) after complete resection of stage IV melanoma. METHODS: After complete resection of ≤5 distant metastases, patients were randomly assigned to BCG+Canvaxin (BCG/Cv) or BCG+placebo (BCG/Pl). The primary endpoint was overall survival (OS); secondary endpoints were disease-free survival (DFS), and immune response measured by skin test (ClinicalTrials...
October 10, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28994212/high-frequency-of-brain-metastases-after-adjuvant-therapy-for-high-risk-melanoma
#7
Wolfram E Samlowski, James Moon, Merle Witter, Michael B Atkins, John M Kirkwood, Megan Othus, Antoni Ribas, Vernon K Sondak, Lawrence E Flaherty
The incidence of CNS progression in patients with high-risk regional melanoma (stages IIIAN2a-IIIC) is not well characterized. Data from the S0008 trial provided an opportunity to examine the role of CNS progression in treatment failure and survival. All patients were surgically staged. Following wide excision and full regional lymphadenectomy, patients were randomized to receive adjuvant biochemotherapy (BCT) or high-dose interferon alfa-2B (HDI). CNS progression was retrospectively identified from data forms...
October 10, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28981385/randomized-open-label-phase-ii-study-evaluating-the-efficacy-and-safety-of-talimogene-laherparepvec-in-combination-with-ipilimumab-versus-ipilimumab-alone-in-patients-with-advanced-unresectable-melanoma
#8
Jason Chesney, Igor Puzanov, Frances Collichio, Parminder Singh, Mohammed M Milhem, John Glaspy, Omid Hamid, Merrick Ross, Philip Friedlander, Claus Garbe, Theodore F Logan, Axel Hauschild, Celeste Lebbé, Lisa Chen, Jenny J Kim, Jennifer Gansert, Robert H I Andtbacka, Howard L Kaufman
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolytic virus to a checkpoint inhibitor. Methods Patients with unresectable stages IIIB to IV melanoma, with no more than one prior therapy if BRAF wild-type, no more than two prior therapies if BRAF mutant, measurable/injectable disease, and without symptomatic autoimmunity or clinically significant immunosuppression were randomly assigned 1:1 to receive talimogene laherparepvec plus ipilimumab or ipilimumab alone...
October 5, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28963614/efficacy-of-vemurafenib-treatment-in-43-metastatic-melanoma-patients-with-braf-mutation-single-institute-retrospective-analysis-early-real-life-survival-data
#9
Kata Czirbesz, Eszter Gorka, Tímea Balatoni, Gitta Pánczél, Krisztina Melegh, Péter Kovács, András Gézsi, Gabriella Liszkay
BRAF inhibitor vemurafenib achieved improved overall survival over chemotherapy and have been approved by the FDA and EMA for the treatment of BRAF-mutated metastatic melanoma. The aim of our retrospective analysis was to determine the efficacy and safety of vemurafenib therapy for BRAF mutated metastatic melanoma and subsequently to prove the clinical benefit for the studied 43 patients, based on real-life data. From November 2012 to October 2015 we have selected 43 BRAF mutated, metastatic melanoma patients, treated with vemurafenib...
September 29, 2017: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/28960564/real-world-treatment-patterns-and-clinical-outcomes-in-advanced-cutaneous-melanoma-patients-in-france
#10
B Sassolas, M T Leccia, C Godard, L Benmahamed, A Flinois, L Levy-Bachelot, C Bédane
BACKGROUND: Since 2011, the management of advanced melanoma has radically changed with the availability of new therapies (immunotherapy and BRAF targeted therapy), and with BRAF testing. OBJECTIVES: Following the introduction of these new therapies, the objectives of this AMEL study were to describe treatment patterns and evaluate overall survival (OS) among unresectable stage III/IV melanoma patients, in a real-life setting in France. METHODS: The AMEL study is a multicentre retrospective record review study...
September 28, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28958277/tumor-mitotic-rate-and-association-with-recurrence-in-sentinel-lymph-node-negative-stage-ii-melanoma-patients
#11
Shachar Laks, Michael O Meyers, Allison M Deal, Jill S Frank, Karyn B Stitzenberg, Jen Jen Yeh, Nancy E Thomas, David W Ollila
Tumor mitotic rate (TMR) is a known prognostic variable in thin melanoma patients. Its significance in stage II melanoma patients is yet to be demonstrated. Retrospective analysis of a prospective melanoma database from 9/1997 to 7/2015 was performed. All stage II melanoma, with documented TMR, and six months of follow-up were included. We evaluated the association of clinicopathologic variables, TMR, as a continuous and categorical variable with recurrence-free survival (RFS) and overall survival (OS) using Cox proportional hazards modeling...
September 1, 2017: American Surgeon
https://www.readbyqxmd.com/read/28951753/comparison-of-electronic-brachytherapy-and-mohs-micrographic-surgery-for-the-treatment-of-early-stage-non-melanoma-skin-cancer-a-matched-pair-cohort-study
#12
Rakesh Patel, Robert Strimling, Stephen Doggett, Mark Willoughby, Kenneth Miller, Lawrence Dardick, Erick Mafong
PURPOSE: High-dose-rate electronic brachytherapy (EBT) provides a non-surgical treatment option for non-melanoma skin cancer (NMSC). This matched-pair cohort study compared the outcomes of treatment with EBT to those of Mohs micrographic surgery (MMS) in patients with NMSC. MATERIAL AND METHODS: At four treatment centers, patients treated with EBT were case matched to patients treated with MMS based on retrospectively-collected patient age, lesion size, location and type, and year of treatment...
August 2017: Journal of Contemporary Brachytherapy
https://www.readbyqxmd.com/read/28937324/impact-of-2-staged-stereotactic-radiosurgery-for-treatment-of-brain-metastases-%C3%A2-2-cm
#13
Lilyana Angelov, Alireza M Mohammadi, Elizabeth E Bennett, Mahmoud Abbassy, Paul Elson, Samuel T Chao, Joshua S Montgomery, Ghaith Habboub, Michael A Vogelbaum, John H Suh, Erin S Murphy, Manmeet S Ahluwalia, Sean J Nagel, Gene H Barnett
OBJECTIVE Stereotactic radiosurgery (SRS) is the primary modality for treating brain metastases. However, effective radiosurgical control of brain metastases ≥ 2 cm in maximum diameter remains challenging and is associated with suboptimal local control (LC) rates of 37%-62% and an increased risk of treatment-related toxicity. To enhance LC while limiting adverse effects (AEs) of radiation in these patients, a dose-dense treatment regimen using 2-staged SRS (2-SSRS) was used. The objective of this study was to evaluate the efficacy and toxicity of this treatment strategy...
September 22, 2017: Journal of Neurosurgery
https://www.readbyqxmd.com/read/28936478/recurrence-rate-of-melanoma-in-situ-when-treated-with-serial-disk-staged-excision-a-case-series
#14
Daniel Garcia, Robert E Eilers, S Brian Jiang
BACKGROUND: Cutaneous melanoma is one of the fastest rising cancer diagnoses in recent years. Melanoma in situ (MIS) constitutes a large proportion of all diagnosed melanomas. While surgical excision is considered the standard of therapy, the literature is not clear on which surgical technique minimizes local recurrence. A common technique is serial staged excision (SSE), in which a series of mapped excisions are made according to histopathological examination of tissue. Previously published recurrence rates for SSE ranges from 0-12%, over a range of 4...
February 2017: Journal of Clinical and Investigative Dermatology
https://www.readbyqxmd.com/read/28923101/durable-response-rate-as-an-endpoint-in-cancer-immunotherapy-insights-from-oncolytic-virus-clinical-trials
#15
Howard L Kaufman, Robert H I Andtbacka, Frances A Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov, Merrick Ross
BACKGROUND: Traditional response criteria may be insufficient to characterize full clinical benefits of anticancer immunotherapies. Consequently, endpoints such as durable response rate (DRR; a continuous response [complete or partial objective response] beginning within 12 months of treatment and lasting ≥6 months) have been employed. There has not, however, been validation that DRR correlates with other more traditional endpoints of clinical benefit such as overall survival. METHODS: We evaluated whether DRR was associated with clinically meaningful measures of benefit (eg, overall survival [OS], quality of life [QoL], or treatment-free interval [TFI]) in a phase 3 clinical trial of an oncolytic virus for melanoma treatment...
September 19, 2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28921907/dual-mapk-pi3k-pathway-inhibition-with-trametinib-and-gsk2141795-does-not-yield-clinical-benefit-in-metastatic-nras-mutant-and-wild-type-melanoma
#16
Alain P Algazi, Rosaura Esteve-Puig, Adi Nosrati, Brian Hinds, Adele Hobbs-Muthukumar, Prachi Nandoskar, Susana Ortiz-Urda, Paul B Chapman, Adil Daud
Aberrant MAPK and PI3K pathway signaling may drive the malignant phenotype in NRAS mutant and BRAF(WT) NRAS(WT) metastatic melanoma. To target these pathways NRAS mutant and BRAF(WT) NRAS(WT) patients received oral trametinib at 1.5 mg daily and GSK2141795 at 50 mg daily in a 2-cohort Simon 2-stage design. Participants had adequate end organ function and no more than 2 prior treatment regimens. Imaging assessments were performed at 8-week intervals. 10 NRAS mutant and 10 BRAF(WT) NRAS(WT) patients were enrolled...
September 16, 2017: Pigment Cell & Melanoma Research
https://www.readbyqxmd.com/read/28919776/safety-pharmacokinetics-and-pharmacodynamics-of-oral-omaveloxolone-rta-408-a-synthetic-triterpenoid-in-a-first-in-human-trial-of-patients-with-advanced-solid-tumors
#17
Ben C Creelan, Dmitry I Gabrilovich, Jhanelle E Gray, Charles C Williams, Tawee Tanvetyanon, Eric B Haura, Jeffrey S Weber, Geoffrey T Gibney, Joseph Markowitz, Joel W Proksch, Scott A Reisman, Mark D McKee, Melanie P Chin, Colin J Meyer, Scott J Antonia
BACKGROUND: Omaveloxolone is a semisynthetic oleanane triterpenoid that potently activates Nrf2 with subsequent antioxidant function. We conducted a first-in-human Phase I clinical trial (NCT02029729) with the primary objectives to determine the appropriate dose for Phase II studies, characterize pharmacokinetic and pharmacodynamic parameters, and assess antitumor activity. METHODS: Omaveloxolone was administered orally once daily continuously in a 28-day cycle for patients with stage 4 relapsed/refractory melanoma or non-small cell lung cancer...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28914692/increasing-suicide-risk-among-cancer-patients-in-lithuania-from-1993-to-2012-a-cancer-registry-based-study
#18
Auguste Kaceniene, Agne Krilaviciute, Jurgita Kazlauskiene, Giedre Bulotiene, Giedre Smailyte
Certain groups of individuals seem to have an increased risk of committing suicide, and a number of studies have reported an increased risk of suicide among cancer patients. In this study, we aim to estimate the risk of suicide among cancer patients in Lithuania over the period 1993-2012. The records of patients diagnosed with primary cancer were extracted from the population-based Lithuanian Cancer Registry and 273 511 cases of first cancer were included in the analysis. Sex, age and calendar period-standardized mortality ratios (SMRs) were calculated by dividing the observed numbers of suicides among cancer patients by the expected number using national rates...
September 2017: European Journal of Cancer Prevention
https://www.readbyqxmd.com/read/28913367/efficacy-of-tumor-infiltrating-lymphocytes-combined-with-ifn-%C3%AE-in-chinese-resected-stage-iii-malignant-melanoma
#19
Wei Li, Linping Xu, Yaomei Wang, Lingdi Zhao, Daniel B Kellner, Quanli Gao
BACKGROUND: This study aims to explore the efficacy of tumor-infiltrating lymphocytes (TIL) along with interferon-α (IFN-α) to treat stage III malignant melanoma (MM) patients in China. METHODS: Between May 2010 and October 2014, 77 patients of stage III MM who underwent surgery were collected in this study. These patients were divided into two groups: patients who received TIL + IFN-α ± RetroNectin-activated cytokine-induced killer cells (R-CIK) in Arm 1 (n = 27) and IFN-α ± R-CIK in Arm 2 (n = 50) as adjuvant therapy...
2017: Journal of Immunology Research
https://www.readbyqxmd.com/read/28894934/tumor-infiltrating-lymphocytes-in-lymph-node-metastases-of-stage-iii-melanoma-correspond-to-response-and-survival-in-nine-patients-treated-with-ipilimumab-at-the-time-of-stage-iv-disease
#20
Stefan Diem, Omar Hasan Ali, Christoph J Ackermann, David Bomze, Viktor H Koelzer, Wolfram Jochum, Daniel E Speiser, Kirsten D Mertz, Lukas Flatz
Prognosis of metastatic melanoma improved with the development of checkpoint inhibitors. The role of tumor infiltrating lymphocytes (TILs) in lymph node metastases of stage III melanoma remains unclear. We retrospectively characterized TILs in primary melanomas and matched lymph node metastases (stage III melanoma) of patients treated with the checkpoint inhibitor ipilimumab. Tumor infiltrating lymphocytes were characterized for CD3, CD4, and CD8 expressions by immunohistochemistry. 4/9 patients (44%) responded to treatment with ipilimumab (1 complete and 2 partial remissions, 1 stable disease)...
September 11, 2017: Cancer Immunology, Immunotherapy: CII
keyword
keyword
62301
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"